[go: up one dir, main page]

WO2004078163A3 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen - Google Patents

Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Download PDF

Info

Publication number
WO2004078163A3
WO2004078163A3 PCT/US2004/006288 US2004006288W WO2004078163A3 WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3 US 2004006288 W US2004006288 W US 2004006288W WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3
Authority
WO
WIPO (PCT)
Prior art keywords
ester
api
acid
heterocyclic ring
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006288
Other languages
French (fr)
Other versions
WO2004078163A2 (en
Inventor
Oern Almarsson
Magali Bourghol Hickey
Matthew Peterson
Brian Moulton
Nair Rodriguez-Hornedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of Michigan System
Transform Pharmaceuticals Inc
University of Michigan Ann Arbor
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of Michigan System
Transform Pharmaceuticals Inc
University of Michigan Ann Arbor
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/006662 external-priority patent/WO2003074474A2/en
Priority claimed from US10/449,307 external-priority patent/US7078526B2/en
Priority claimed from PCT/US2003/019574 external-priority patent/WO2004000284A1/en
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/en
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/en
Priority to CA002514733A priority Critical patent/CA2514733A1/en
Application filed by University of South Florida, University of Michigan System, Transform Pharmaceuticals Inc, University of Michigan Ann Arbor, University of South Florida St Petersburg filed Critical University of South Florida
Priority to JP2006508979A priority patent/JP2007524596A/en
Priority to US10/546,963 priority patent/US20070059356A1/en
Priority to EP04715190A priority patent/EP1631260A2/en
Priority to PCT/US2004/009947 priority patent/WO2004089313A2/en
Priority to US10/551,014 priority patent/US20060223794A1/en
Priority to US10/926,842 priority patent/US7446107B2/en
Priority to PCT/US2004/028456 priority patent/WO2005092884A1/en
Priority to JP2007500742A priority patent/JP2007525502A/en
Priority to EP04782868A priority patent/EP1718640A4/en
Priority to JP2006525508A priority patent/JP4842819B2/en
Priority to EP20040783308 priority patent/EP1670753A4/en
Publication of WO2004078163A2 publication Critical patent/WO2004078163A2/en
Publication of WO2004078163A3 publication Critical patent/WO2004078163A3/en
Anticipated expiration legal-status Critical
Priority to IL173575A priority patent/IL173575A0/en
Priority to NO20060669A priority patent/NO20060669L/en
Priority to US12/234,420 priority patent/US20090088443A1/en
Priority to IL199140A priority patent/IL199140A/en
Priority to US12/792,415 priority patent/US20100311701A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
PCT/US2004/006288 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Ceased WO2004078163A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP04715190A EP1631260A2 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/546,963 US20070059356A1 (en) 2002-05-31 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA002514733A CA2514733A1 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006508979A JP2007524596A (en) 2003-02-28 2004-02-26 Co-crystal pharmaceutical composition
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment
PCT/US2004/009947 WO2004089313A2 (en) 2003-04-01 2004-03-31 Novel olanzapine forms and related methods of treatment
US10/926,842 US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
PCT/US2004/028456 WO2005092884A1 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
JP2007500742A JP2007525502A (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods for their production and use
EP04782868A EP1718640A4 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
JP2006525508A JP4842819B2 (en) 2003-09-04 2004-09-04 Modafinil composition
EP20040783308 EP1670753A4 (en) 2003-09-04 2004-09-04 Modafinil compositions
IL173575A IL173575A0 (en) 2003-09-04 2006-02-07 Modafinil compositions
NO20060669A NO20060669L (en) 2003-09-11 2006-02-10 Modafinilsammensetninger
US12/234,420 US20090088443A1 (en) 2002-02-15 2008-09-19 Novel crystalline forms of conazoles and methods of making and using the same
IL199140A IL199140A (en) 2003-09-04 2009-06-03 Modafinil compositions
US12/792,415 US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
PCT/US2003/006662 WO2003074474A2 (en) 2002-03-01 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
USPCT/US03/06662 2003-03-03
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US46396203P 2003-04-18 2003-04-18
US60/463,962 2003-04-18
US10/449,307 2003-05-30
US10/449,307 US7078526B2 (en) 2002-05-31 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US10/601,092 2003-06-20
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
USPCT/US03/19574 2003-06-20
US48706403P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
USPCT/US03/27772 2003-09-04
PCT/US2003/027772 WO2004078161A1 (en) 2003-02-28 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 2003-09-11
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
USPCT/US03/41273 2003-12-24
PCT/US2003/041273 WO2004061433A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06

Related Parent Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2003/006662 Continuation-In-Part WO2003074474A2 (en) 2002-02-15 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
US10/449,307 Continuation-In-Part US7078526B2 (en) 2002-02-15 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/637,829 Continuation-In-Part US20040053853A1 (en) 2002-02-15 2003-08-08 Topiramate salts and compositions comprising and methods of making and using the same
PCT/US2003/027772 Continuation-In-Part WO2004078161A1 (en) 2002-02-15 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 Continuation-In-Part US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/926,842 Continuation-In-Part US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
US12/792,415 Continuation US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Publications (2)

Publication Number Publication Date
WO2004078163A2 WO2004078163A2 (en) 2004-09-16
WO2004078163A3 true WO2004078163A3 (en) 2005-01-20

Family

ID=56290526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006288 Ceased WO2004078163A2 (en) 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Country Status (4)

Country Link
EP (1) EP1631260A2 (en)
JP (1) JP2007524596A (en)
CA (1) CA2514733A1 (en)
WO (1) WO2004078163A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
US9532993B2 (en) 2011-11-25 2017-01-03 Nuformix Limited Aprepitant L-proline solvates—compositions and cocrystals
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Families Citing this family (409)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129714A1 (en) 2001-06-22 2003-01-02 Bayer Ag Topical application of thiazolylamides
US7078526B2 (en) * 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (en) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ Multi-component solid phase containing at least one active pharmaceutical ingredient
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP4842819B2 (en) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド Modafinil composition
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
DE102005014248A1 (en) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N- [5- (aminosulfonyl) -4-methyl-1,3-thiazol-2-yl] -N-methyl-2- [4- (2-pyridinyl) phenyl] acetamide
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
US20070099237A1 (en) * 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR057882A1 (en) 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
EP1962600B1 (en) * 2005-12-08 2013-05-01 New Form Pharmaceuticals Inc. Metronidazole cocrystals
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
JP2010505952A (en) * 2006-10-10 2010-02-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ New crystals of (S)-(+)-2- (2-chlorophenyl) -2-hydroxy-ethylcarbamate
EP1973528B1 (en) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
WO2008108639A1 (en) * 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
EP2167043A4 (en) 2007-06-06 2013-05-01 Univ South Florida NUTRACEUTICAL COMPOSITIONS OF CO-CRISTAL
WO2009094155A1 (en) * 2008-01-22 2009-07-30 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
WO2009140466A2 (en) * 2008-05-14 2009-11-19 Dr. Reddy's Laboratories Ltd. Linezolid co-crystals
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009152347A2 (en) * 2008-06-13 2009-12-17 Bionevia Pharmaceuticals Inc. Crystalline forms of zotepine hydrochloride
US8258155B2 (en) 2008-06-30 2012-09-04 Mutual Pharmaceutical Company, Inc. Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
CA2738866A1 (en) * 2008-08-06 2010-02-11 Bionevia Pharmaceuticals, Inc. Flupirtine hydrochloride maleic acid cocrystal
LT2326632T (en) 2008-09-06 2017-09-25 Bionevia Pharmaceuticals, Inc. Novel choline cocrystal of epalrestat
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2199274A1 (en) * 2008-12-16 2010-06-23 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and paracetamol
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
KR20100091127A (en) * 2009-02-09 2010-08-18 주식회사 한독약품 Novel salts of adefovir dipivoxil and method for the preparation of the same
JP5558875B2 (en) * 2009-03-19 2014-07-23 日本曹達株式会社 Novel inclusion complex, epoxy resin composition and epoxy resin composition for semiconductor encapsulation
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR20120036850A (en) 2009-05-15 2012-04-18 노파르티스 아게 Benzoxazolone derivatives as aldosterone synthase inhibitors
KR101338555B1 (en) 2009-05-15 2013-12-09 노파르티스 아게 Aryl pyridine as aldosterone synthase inhibitors
US20120129923A1 (en) * 2009-05-20 2012-05-24 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
KR101442897B1 (en) 2009-05-28 2014-09-23 노파르티스 아게 Substituted aminopropionic derivatives as neprilysin inhibitors
AR077490A1 (en) 2009-07-21 2011-08-31 Novartis Ag TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF A HYPERPROLIFERATIVE SKIN CONDITION
UY32799A (en) 2009-07-24 2011-02-28 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP3295935B1 (en) 2009-07-31 2020-07-22 Grünenthal GmbH Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2281558A1 (en) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
KR20120089463A (en) 2009-08-20 2012-08-10 노파르티스 아게 Heterocyclic oxime compounds
CA2771936A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US20120165306A1 (en) 2009-09-04 2012-06-28 Barsanti Paul A Pyrazinylpyridines useful for the treatment of proliferative diseases
US20110130380A1 (en) 2009-09-04 2011-06-02 Barsanti Paul A Heteroaryl Kinase Inhibitors
CN102498107A (en) 2009-09-04 2012-06-13 诺瓦提斯公司 Heteroaryl compounds as kinase inhibitors
EA020586B1 (en) 2009-09-10 2014-12-30 Новартис Аг SULFONAMIDES AS INHIBITORS OF Bcl-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER
IN2012DN02139A (en) 2009-09-10 2015-08-07 Novartis Ag
EP2325172A1 (en) * 2009-11-02 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of celecoxib and L-proline
BR112012010519A2 (en) 2009-11-04 2017-12-05 Novartis Ag heterocyclic sulfonamide derivatives
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
JP2013515032A (en) 2009-12-21 2013-05-02 ノバルティス アーゲー Disubstituted heteroaryl fused pyridines
JP2013515033A (en) 2009-12-21 2013-05-02 ノバルティス アーゲー Diaza-spiro [5.5] undecanes as orexin receptor antagonists
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
BR112012015916A2 (en) 2009-12-31 2017-04-25 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8318807B2 (en) * 2010-02-03 2012-11-27 Laurus Labs Private Limited Pterostilbene cocrystals
UY33236A (en) 2010-02-25 2011-09-30 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
CN102933205B (en) * 2010-04-28 2014-08-13 诺弗米克斯有限公司 Cilostazol cocrystals and compositions
US20130053381A1 (en) 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
JP2013528635A (en) 2010-06-17 2013-07-11 ノバルティス アーゲー Biphenyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
BR112012004154A2 (en) 2010-07-13 2017-05-30 Novartis Ag "oxazine derivatives and their use in the treatment of neurological disorders"
SI2593452T1 (en) 2010-07-14 2017-06-30 Novartis Ag Ip receptor agonist heterocyclic compounds
AU2011281546B2 (en) 2010-07-22 2014-07-10 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
JP2013537180A (en) 2010-09-13 2013-09-30 ノバルティス アーゲー Triazine-oxadiazoles
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
BR112013008140A8 (en) 2010-09-20 2018-04-03 Envivo Pharmaceuticals Inc "IMIDAZOTRIAZINONE COMPOUNDS".
BR112013008510A2 (en) 2010-10-08 2016-07-05 Novartis Ag vitamin e ns3 sulfamide inhibitor formulations
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
UY33794A (en) 2010-12-13 2012-07-31 Novartis Ag DIMERIC INHIBITORS OF THE IAP
EP2651917A1 (en) 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
CU24152B1 (en) 2010-12-20 2016-02-29 Irm Llc 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS
EP2655326A1 (en) 2010-12-20 2013-10-30 Novartis AG 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
CN103370315A (en) 2010-12-20 2013-10-23 Irm责任有限公司 Compositions and methods for modulating farnesoid x receptors
WO2012087521A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
MX347391B (en) 2011-01-04 2017-04-25 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd).
CN103429589A (en) 2011-01-12 2013-12-04 诺瓦提斯公司 Oxazine derivatives and their use in the treatment of neurological disorders
MX336966B (en) 2011-01-13 2016-02-08 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders.
WO2012095521A1 (en) 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
WO2012098501A1 (en) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Febuxostat co-crystals
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
MX2013009767A (en) 2011-02-25 2013-10-01 Irm Llc Compounds and compositions as trk inhibitors.
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
JP2014507465A (en) 2011-03-08 2014-03-27 ノバルティス アーゲー Fluorophenyl bicyclic heteroaryl compounds
JP2014508814A (en) * 2011-03-24 2014-04-10 ユニバーシティ・オブ・サウス・フロリダ Lithium composition
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2012140596A1 (en) 2011-04-14 2012-10-18 Novartis Ag Glycoside derivatives and uses thereof
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
EP2517700B1 (en) * 2011-04-28 2013-07-17 Zentiva, k.s. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
UY34072A (en) 2011-05-17 2013-01-03 Novartis Ag INDOL SUBSTITUTED DERIVATIVES
UY34094A (en) 2011-05-27 2013-01-03 Novartis Ag DERIVATIVES OF PIPERIDINE 3-ESPIROCYCLIC AS AGRONISTS OF GHRELINE RECEPTORS
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
BR112014000333A2 (en) 2011-07-08 2017-02-07 Novartis Ag atherosclerosis treatment method in subjects with high triglyceride
KR20140048235A (en) 2011-07-08 2014-04-23 노파르티스 아게 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EP2729466B1 (en) 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MX2014001086A (en) 2011-07-27 2014-02-27 Novartis Ag Pyrazoline derivatives and their use as selective androgen receptor modulators.
UY34278A (en) 2011-08-25 2013-04-05 Novartis Ag NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EA201490539A1 (en) 2011-09-01 2014-06-30 АйАрЭм ЭлЭлСи COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
KR20140071383A (en) 2011-09-01 2014-06-11 아이알엠 엘엘씨 Compounds and compositions as c-kit kinase inhibitors
EA026152B1 (en) 2011-09-01 2017-03-31 Новартис Аг COMPOUNDS AND COMPOSITIONS AS c-kit KINASE INHIBITORS
MX2014002486A (en) 2011-09-01 2014-12-08 Irm Llc Compounds and compositions as pdgfr kinase inhibitors.
JO3192B1 (en) 2011-09-06 2018-03-08 Novartis Ag Benzothiazolone compound
UY34329A (en) 2011-09-15 2013-04-30 Novartis Ag TRIAZOLOPIRIDINE COMPOUNDS
ES2558457T3 (en) 2011-09-16 2016-02-04 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (en) 2011-09-16 2021-12-02 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
TW201321353A (en) 2011-10-08 2013-06-01 Novartis Ag Carbamate/urea derivatives
US9284284B2 (en) 2011-10-13 2016-03-15 Novartis Ag Oxazine derivatives and their use in the treatment of disease
TWI580442B (en) 2011-10-19 2017-05-01 傑特大學 Pharmaceutical nanosuspension
JP2014530851A (en) 2011-10-21 2014-11-20 ノバルティスアーゲー Quinazoline derivatives as PI3K modulators
PL2771342T3 (en) 2011-10-28 2016-11-30 Purine derivatives and their use in the treatment of disease
BR112014012815A8 (en) 2011-11-28 2017-06-20 Novartis Ag trifluoromethyl oxadiazole derivatives and their use in the treatment of disease
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
MA37142B1 (en) 2011-12-22 2019-07-31 Novartis Ag Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
UY34572A (en) 2012-01-13 2013-09-02 Novartis Ag AGONIST HETEROCYCLIC COMPOUNDS OF THE IP RECEIVER
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
UY34646A (en) 2012-03-02 2013-10-31 Novartis Ag ESPIROHIDANTOINE COMPOUNDS AND THEIR USE AS SELECTIVE MODULATORS OF THE ANDROGEN RECEIVER
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
SG11201406526WA (en) 2012-04-27 2014-11-27 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
TW201348235A (en) 2012-05-03 2013-12-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AP2014008040A0 (en) 2012-05-04 2014-10-31 Novartis Ag Complement pathway modulators and uses thereof
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
JP6171003B2 (en) 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
EP2861578A1 (en) 2012-06-06 2015-04-22 Irm Llc Compounds and compositions for modulating egfr activity
JP6211072B2 (en) * 2012-06-15 2017-10-11 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Multi-component crystals comprising dasatinib and a selected co-crystal former
MX2014015933A (en) 2012-06-20 2015-07-17 Novartis Ag Complement pathway modulators and uses thereof.
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
JP6155332B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
WO2014002057A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN104640855B (en) 2012-06-28 2017-08-29 诺华股份有限公司 Complement is by way of conditioning agent and application thereof
ES2648962T3 (en) 2012-06-28 2018-01-09 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104684910B (en) 2012-07-12 2016-10-12 诺华股份有限公司 Complement pathway modulators and uses thereof
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
KR101303803B1 (en) 2012-08-02 2013-09-04 순천향대학교 산학협력단 Preparation of co-crystals of various drug substances including cabamazepine-saccharin co-crystals by anti-solvent method
BR112015003058A2 (en) 2012-08-13 2017-07-04 Novartis Ag Bicyclic derivatives of heteroaryl cycloalkyl diamine as spleen tyrosine kinases inhibitors (syk)
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
MX351741B (en) 2012-08-30 2017-10-26 Novartis Ag Salts of benzothiazolone compound as beta-2-adrenoceptor agonist.
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033617A1 (en) 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
EA028093B1 (en) 2012-09-07 2017-10-31 Новартис Аг Indole carboxamide derivatives and uses thereof
ES2612885T3 (en) 2012-09-19 2017-05-19 Novartis Ag Dihydro-pyrrolidino-pyrimidines as kinase inhibitors
EP2900237A1 (en) 2012-09-25 2015-08-05 Novartis AG Compounds for use in gastric complication
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
JP6243918B2 (en) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド PKM2 modulators and methods for their use
CA2888194A1 (en) 2012-11-07 2014-05-15 Novartis Ag Substituted indole derivatives
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
PT2925757T (en) 2012-11-19 2018-01-09 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
ES2709034T3 (en) 2012-12-13 2019-04-12 Novartis Ag Pyrimido [4,5-b] quinoline-4,5 (3h, 10h) -diones as suppressors of nonsense mutations
EP2931716B1 (en) 2012-12-13 2016-11-02 Novartis Ag Pyridone derivatives and uses thereof in the treatment of tuberculosis
KR20150097660A (en) 2012-12-19 2015-08-26 노파르티스 아게 Tricyclic compounds for inhibiting the cftr channel
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
KR20150095925A (en) 2012-12-19 2015-08-21 노파르티스 아게 Tricyclic compounds as cftr inhibitors
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
HRP20180958T1 (en) 2013-02-14 2018-07-27 Novartis Ag BISPHENOLBUTANPHOSPHONIC ACID SUBSTITUTED DERIVATIVES AS INHIBITORS FOR NEP (NEUTRAL ENDOPEPTIDASE)
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
ES2637802T3 (en) 2013-02-28 2017-10-17 Novartis Ag Formulation comprising a benzothiazolone compound
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
UY35400A (en) 2013-03-15 2014-10-31 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
WO2014167528A1 (en) 2013-04-11 2014-10-16 Novartis Ag Spiropyrazolopyridine derivatives and uses thereof for the treatment of viral infections
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CA2913697A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PL3004112T3 (en) 2013-05-28 2018-02-28 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
PT3004108T (en) 2013-05-28 2018-01-24 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
EP3022201A1 (en) 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
ES2742077T3 (en) 2013-07-18 2020-02-13 Novartis Ag Autotaxin inhibitors comprising a cyclic benzyl amide heteroaromatic ring core
US20160184305A1 (en) 2013-07-31 2016-06-30 Novartis Ag 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions
JP6203954B2 (en) 2013-10-25 2017-09-27 ノバルティス アーゲー Fused bicyclic pyridyl derivatives as FGFR4 inhibitors
WO2015066241A1 (en) 2013-10-30 2015-05-07 Novartis Ag 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
HUE039306T2 (en) 2013-11-01 2018-12-28 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
CA2930290C (en) * 2013-11-11 2023-02-28 Collaborative Medicinal Development, Llc Metal complexes and methods of treatment
WO2015075665A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
JP6636925B2 (en) 2013-12-17 2020-01-29 ノバルティス アーゲー Cytotoxic peptides and conjugates thereof
UA117046C2 (en) 2013-12-19 2018-06-11 Новартіс Аг [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
PT3083564T (en) 2013-12-20 2018-11-07 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
PT3122745T (en) 2014-03-24 2019-04-30 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
TW201602089A (en) 2014-04-17 2016-01-16 諾華公司 Polycyclic HERG activators
ES2687393T3 (en) 2014-04-22 2018-10-25 Novartis Ag Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MA39972B1 (en) 2014-05-13 2024-10-31 Novartis Ag CHONDROGENESIS-INDUCING COMPOUNDS AND COMPOSITIONS
US20170088546A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US20170088545A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
TW201946921A (en) 2014-05-14 2019-12-16 瑞士商諾華公司 Carboxamide derivatives
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
AR100706A1 (en) 2014-06-03 2016-10-26 Novartis Ag NAFTIRIDINADIONA DERIVATIVES
JP6560257B2 (en) 2014-06-03 2019-08-14 ノバルティス アーゲー Pyrimido [4,5-b] quinoline-4,5 (3H, 10H) -dione derivative
CN106414443B (en) 2014-06-03 2018-10-26 诺华股份有限公司 Pyridopyrimidine dione derivative
SG11201609462RA (en) 2014-06-13 2016-12-29 Novartis Ag Auristatin derivatives and conjugates thereof
TW201625584A (en) 2014-07-02 2016-07-16 諾華公司 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW201625586A (en) 2014-07-02 2016-07-16 諾華公司 Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
TW201625601A (en) 2014-07-02 2016-07-16 諾華公司 Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
US10160726B2 (en) 2014-08-06 2018-12-25 Novartis Ag Quinolone derivatives as antibacterials
WO2016038583A1 (en) 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as kinase inhibitors
JP6636014B2 (en) 2014-09-12 2020-01-29 ノバルティス アーゲー Compounds and compositions as RAF kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
EP3197275B1 (en) * 2014-09-24 2021-11-24 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
AU2015365455B2 (en) 2014-12-16 2019-01-17 Novartis Ag Isoxazole hydroxamic acid compounds as LpxC inhibitors
TN2017000204A1 (en) 2014-12-23 2018-10-19 Novartis Ag Triazolopyrimidine compounds and uses thereof
US10189813B2 (en) 2015-03-25 2019-01-29 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016174616A1 (en) 2015-04-30 2016-11-03 Novartis Ag Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2016205785A1 (en) * 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
KR20180021805A (en) * 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 Pharmaceutical co-crystal compositions and uses thereof
CA2999268A1 (en) 2015-09-24 2017-03-30 Pain Therapeutics, Inc. Cocrystals of naloxone and naltrexone
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
PH12018501019B1 (en) 2015-11-26 2023-03-15 Novartis Ag Diamino pyridine derivatives
CN105399664A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with 2,5-dihydroxybenzoic acid as precursor and preparation method thereof
CN105541701A (en) * 2015-12-11 2016-05-04 吉林大学珠海学院 Pharmaceutical cocrystal of deferiprone with maleic acid as precursor, and preparation method thereof
CN105399665A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with p-hydroxybenzoic acid as precursor and preparation method thereof
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
MX2018007517A (en) 2015-12-18 2018-08-01 Novartis Ag Tricyclic compounds and compositions as kinase inhibitors.
HK1254636A1 (en) 2015-12-18 2019-07-26 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
TW201728325A (en) 2016-01-21 2017-08-16 諾華公司 Compounds and compositions for the treatment of cryptosporidiosis
US20200270265A1 (en) 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
CN110267945A (en) 2016-03-01 2019-09-20 诺华股份有限公司 Cyano-substituted indole compounds and their use as LSD1 inhibitors
CN108699059B (en) 2016-03-08 2021-06-18 诺华股份有限公司 Tricyclic compounds useful in the treatment of orthomyxovirus infection
FI3433257T3 (en) 2016-03-24 2024-01-08 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
CN109906224B (en) 2016-06-20 2022-02-25 诺华股份有限公司 Triazolopyridine compounds and uses thereof
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
WO2017219948A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
CN106432136B (en) * 2016-06-30 2018-12-25 中国药科大学 A kind of Hydrochioro and atenolol are total to unformed system and preparation method thereof
KR102559539B1 (en) 2016-07-20 2023-07-26 노파르티스 아게 Aminopyridine derivatives and their use as selective alk-2 inhibitors
JOP20170169A1 (en) 2016-08-29 2019-01-30 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
MX382383B (en) 2016-09-09 2025-03-13 Novartis Ag COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF TOLL-LIKE ENDOSOMAL RECEPTORS
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
LT3515894T (en) 2016-09-23 2021-07-26 Novartis Ag INDAZOLE COMPOUNDS FOR USE IN CASE OF TROUBLESHOOTING
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
TW201819380A (en) 2016-10-18 2018-06-01 瑞士商諾華公司 Fused tetracyclic pyridone compounds as antivirals
KR20190075120A (en) 2016-11-10 2019-06-28 노파르티스 아게 BMP Reinforcement
WO2018141749A1 (en) 2017-02-01 2018-08-09 Medivir Ab Therapeutic applications of malt1 inhibitors
CN110461835A (en) 2017-03-24 2019-11-15 诺华股份有限公司 Isoxazole carboxamide compound and its use
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
UY37718A (en) 2017-05-05 2018-11-30 Novartis Ag 2-TRYCLINAL QUINOLINONES AS ANTIBACTERIAL AGENTS
UY37774A (en) 2017-06-19 2019-01-31 Novartis Ag SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
WO2019087162A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
WO2019087163A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
CN111315749A (en) 2017-11-17 2020-06-19 诺华股份有限公司 Novel dihydroisoxazole compounds and their use in the treatment of hepatitis b
CR20200211A (en) 2017-11-24 2020-06-19 Novartis Ag Pyridinone derivatives and their use as selective alk-2 inhibitors
WO2019123285A1 (en) 2017-12-20 2019-06-27 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
EP3730141A4 (en) 2017-12-21 2021-10-13 Kyorin Pharmaceutical Co., Ltd. THERAPEUTIC AGENT FOR NOCTURAL POLLAKIURIA
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
EP3755683A1 (en) * 2018-02-23 2020-12-30 Center for Intelligent Research in Crystal Engineering, S.L. Cocrystals of ubiquinol and compositions comprising them
EP3759113B1 (en) 2018-02-28 2024-09-11 Novartis AG 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019223632A1 (en) 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2019244049A1 (en) 2018-06-19 2019-12-26 Novartis Ag Cyanotriazole compounds and uses thereof
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
LT3837256T (en) 2018-08-17 2023-06-12 Novartis Ag UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
BR112021005263A2 (en) 2018-09-21 2021-06-15 Novartis Ag isoxazole carboxamide compounds and uses thereof
TW202028208A (en) * 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide solid forms
US20220033407A1 (en) 2018-12-18 2022-02-03 Novartis Ag N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease
TWI828839B (en) 2019-01-11 2024-01-11 瑞士商諾華公司 Methods of treating hidradenitis suppurativa using lta4h inhibitors
MA54755A (en) 2019-01-18 2021-11-24 Biogen Ma Inc IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
WO2020154581A1 (en) * 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal
CN113747895A (en) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 Compositions comprising PKM2 modulators and methods of treatment therewith
BR112021024668A2 (en) 2019-06-10 2022-05-31 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD and bronchiectasis
CR20220036A (en) 2019-06-27 2022-05-04 Biogen Ma Inc 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
UY38766A (en) 2019-06-27 2021-01-29 Biogen Ma Inc DERIVATIVES OF IMIDAZO [1,2-A] PYRIDINYL AND THEIR USE IN THE TREATMENT OF DISEASES
AR119819A1 (en) 2019-08-28 2022-01-12 Novartis Ag 1,3-HETEROARYL SUBSTITUTED DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
TW202122078A (en) 2019-09-06 2021-06-16 瑞士商諾華公司 Methods of treating liver disease using lta4h inhibitors
JP7417715B2 (en) 2019-09-26 2024-01-18 ノバルティス アーゲー Antiviral pyrazolopyridinone compounds
JP2021054781A (en) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド Co-crystalline efinaconazole and method for producing the same
PE20230159A1 (en) 2019-12-18 2023-02-01 Novartis Ag 3-(5-METHOXY-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONE DERIVATIVES AND USES
MX2022008931A (en) 2020-01-22 2022-10-18 Benevolentai Bio Ltd Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds.
BR112022013156A2 (en) 2020-01-22 2022-10-18 Benevolentai Bio Ltd PHARMACEUTICAL COMPOSITIONS AND THEIR USES
EP3884938A1 (en) 2020-03-25 2021-09-29 ArtemiFlow GmbH 1,2,4-trioxane compounds and compositions comprising the same for use in the treatment of covid-19
CA3176618A1 (en) 2020-04-20 2021-10-28 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
KR20230024887A (en) 2020-04-20 2023-02-21 노파르티스 아게 Antiviral 1,3-di-oxo-indene compounds
CN113582927B (en) * 2020-04-30 2023-07-04 苏州恩华生物医药科技有限公司 Celecoxib and pregabalin co-amorphous substance and preparation method thereof
KR20230028269A (en) 2020-05-13 2023-02-28 씨에이치디아이 파운데이션, 인코포레이티드 HTT modulators to treat Huntington's disease
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
TW202214652A (en) 2020-06-16 2022-04-16 瑞士商諾華公司 Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as cav1.2 activators
LT4214210T (en) 2020-09-17 2025-07-25 Novartis Ag Compounds and compositions as sppl2a inhibitors
CN112552189A (en) * 2020-11-10 2021-03-26 中国海洋大学 Pharmaceutical co-crystal of amantadine hydrochloride and resveratrol and preparation method thereof
CN112521292B (en) * 2020-12-18 2022-02-11 深圳市萱嘉生物科技有限公司 Eutectic crystal of betaine and organic acid and preparation method and application thereof
IL303966A (en) 2020-12-22 2023-08-01 Biogen Ma Inc Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
WO2022140415A1 (en) 2020-12-22 2022-06-30 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
US20240360157A1 (en) 2021-01-07 2024-10-31 Biogen Ma Inc. Tyk2 inhibitors
JP2024509625A (en) 2021-03-15 2024-03-04 ノバルティス アーゲー Benzisoxazole derivatives and their uses
UY39671A (en) 2021-03-15 2022-10-31 Novartis Ag Pyrazolopyridine derivatives and their uses.
UY39681A (en) 2021-03-26 2022-10-31 Novartis Ag 1,3-Substituted Cyclobutyl Derivatives and Their Uses
US20240182436A1 (en) 2021-04-10 2024-06-06 Sumitomo Pharma America, Inc. Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereof
WO2022217232A1 (en) 2021-04-10 2022-10-13 Sunovion Pharmaceuticals Inc. Chromans and benzofurans as 5-ht1a and taar1 agonists
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
UY39786A (en) 2021-05-26 2023-01-31 Novartis Ag Triazolopyrimidine derivatives and their use in the treatment of diseases
BR112023024905A2 (en) 2021-06-03 2024-02-20 Novartis Ag 3-(5-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USES
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
WO2023275796A1 (en) 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
CN117980292A (en) 2021-07-22 2024-05-03 诺华股份有限公司 Substituted pyridone compounds for treating orthomyxovirus infections
AU2022348905A1 (en) 2021-09-23 2024-04-11 Sumitomo Pharma America, Inc. Methods of treating metabolic disorders
CN113845438B (en) * 2021-10-12 2023-02-21 河北大学 A kind of paracetamol-piracetam medicine co-crystal and preparation method thereof
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
CN114031515B (en) * 2021-11-29 2022-10-21 河北大学 Acetaminophen-ibuprofen pharmaceutical co-crystal and preparation method thereof
JP2024545200A (en) 2021-12-13 2024-12-05 ノバルティス アーゲー Pyridine-3-carboxylate compounds as CaV1.2 activators
KR20240138095A (en) 2022-01-24 2024-09-20 노파르티스 아게 Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses
CN114644669B (en) * 2022-03-10 2025-01-03 华润紫竹药业有限公司 A preparation method of progesterone co-crystal and its application
JP2025511100A (en) 2022-04-01 2025-04-15 ノバルティス アーゲー Complement factor B inhibitors and uses thereof
CN114835657A (en) * 2022-06-10 2022-08-02 大连工业大学 Method for regulating and controlling ethenzamide-saccharin eutectic crystal polycrystalline type based on ionic liquid
EP4547674A1 (en) 2022-07-01 2025-05-07 Biogen MA Inc. Tyk2 inhibitors
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
UY40470A (en) 2022-10-12 2024-05-15 Novartis Ag TRICYCLIC COMPOUNDS AND THEIR USES
WO2024105553A1 (en) 2022-11-16 2024-05-23 Novartis Ag Bicyclic heterocycles and their use as wrn inhibitors
US20240197715A1 (en) 2022-11-18 2024-06-20 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024118488A1 (en) 2022-11-28 2024-06-06 Sumitomo Pharma America, Inc. 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof
WO2024146617A1 (en) 2023-01-04 2024-07-11 甘李药业股份有限公司 Compound and method for targeted degradation of androgen receptor
CN116162053B (en) * 2023-01-10 2025-01-14 山东省分析测试中心 Gliclazide-piperazine eutectic crystal and preparation method thereof
CN120676942A (en) 2023-02-23 2025-09-19 诺华股份有限公司 TEAD inhibitor and HER2 inhibitor combination for the treatment of cancer
CN120659608A (en) 2023-02-23 2025-09-16 诺华股份有限公司 TEAD inhibitor and KRAS G12D inhibitor combination for the treatment of cancer
EP4688778A1 (en) 2023-04-07 2026-02-11 Biogen MA Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
TW202506103A (en) 2023-04-24 2025-02-16 瑞士商諾華公司 Antiviral 1,3-di-oxo-indene compounds
CN121219288A (en) 2023-05-24 2025-12-26 诺华股份有限公司 Naphthyridinone derivatives for use in the treatment of diseases or disorders
AR133953A1 (en) 2023-09-29 2025-11-19 Novartis Ag COMPLEMENT FACTOR B INHIBITORS AND THEIR USES
US20250263416A1 (en) 2024-02-15 2025-08-21 Incyte Corporation SPPL2a INHIBITORS
CN118078830B (en) * 2024-03-13 2025-09-23 海南海和制药有限公司 A method for preparing a pharmaceutical composition containing fluorouracil
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof
WO2025254068A1 (en) * 2024-06-03 2025-12-11 マルホ株式会社 Novel cocrystal
WO2025255488A2 (en) * 2024-06-06 2025-12-11 Karuna Therapeutics, Inc. Xanomeline quercetin complexes and trospium salts
CN120987943A (en) * 2025-10-21 2025-11-21 东华大学 A eutectic material, a hydrated physical mixture, and its preparation and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500862D0 (en) * 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
JP4923182B2 (en) * 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド Celecoxib and nicotinamide co-crystal and pharmaceutical composition containing the co-crystal

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries", 1995, ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 115-148, ISSN: 0108-7681, XP002960386 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9532993B2 (en) 2011-11-25 2017-01-03 Nuformix Limited Aprepitant L-proline solvates—compositions and cocrystals
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2007524596A (en) 2007-08-30
EP1631260A2 (en) 2006-03-08
CA2514733A1 (en) 2004-09-16
WO2004078163A2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
WO2004078163A3 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003272270A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
Corvino et al. Trends in H2S-donors chemistry and their effects in cardiovascular diseases
McBean Cysteine, glutathione, and thiol redox balance in astrocytes
Treuter et al. Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation
Khodade et al. Development of S-substituted thioisothioureas as efficient hydropersulfide precursors
BR9914858A (en) Prostaglandin endoperoxide biosynthesis inhibitors h
BRPI0613371B8 (en) cartridge for the storage and release of a two-phase compound
RU2016150386A (en) HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
ITMI20011733A0 (en) HYDROXAMIC ACID DERIVATIVES INHIBITORS OF HISTONE DEACETYLASE ENZYMES, AS NEW ANTI-INFLAMMATORY DRUGS INHIBITING THE SYNTHESIS OF CITOC
Geurs et al. The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs
HN2002000156A (en) BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
WO2009043049A3 (en) Pharmaceutical formulations
EP1726580A4 (en) AMINOPHENYLPROPANSÄUREDERIVAT
CL2003002611A1 (en) COMPOUNDS DERIVED FROM THE HYDROXAMIC THIOPHEN ACID, 2-HYDROXAMIDE-5 - [(ARIL OR HETEROARIL) -DISUTITUTED-METHYL] -AMIDE OF THE THYMPHENE-2,5-DICARBOXYL DYNAMIC ACID, PHARMACEUTICAL COMPOSITION FOR PREPARATION AND USE D
Zheng-Nan et al. Prodrugs of hydrogen sulfide and related sulfur species: recent development
MX344778B (en) COMBINATION OF ORAL MEDICINES UNITED BY A WRAP.
ATE432972T1 (en) MULTI-COMPONENT THIN-TO-THICK SYSTEM
AR052523A1 (en) PHARMACEUTICAL COMPOSITIONS OF AN NON-STEROID ANTI-INFLAMMATORY PHARMACO
HK1085137A (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005046727A3 (en) Ibuprofen-containing soft gelatin capsules
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
Almarsson et al. Pharmaceutical co-crystal compositions
BR0304303B1 (en) Composition for a low viscosity hydrophobic thickening system for the thickening of an aqueous polymer containing system, and methods for providing a low viscosity thickening system for an aqueous polymer containing system and for increasing the viscosity of an aqueous polymer containing system
BRPI0702769A (en) naphthalene compounds, processes for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2514733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007059356

Country of ref document: US

Ref document number: 10546963

Country of ref document: US

Ref document number: 2006508979

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10546963

Country of ref document: US